生元泽通

Shengyuan Zetong is a biotechnology company based in Beijing, China, specializing in the development of next-generation exosome-based therapeutics. The company leverages a proprietary platform that utilizes milk-derived exosomes as a robust vehicle for the oral delivery of complex therapeutic payloads, including biologics and nucleic acids. This innovative approach aims to overcome traditional barriers to oral drug stability and absorption, potentially transforming the treatment landscape for chronic conditions. Their current pipeline focuses on high-unmet-need areas such as inflammatory bowel disease and oncology. Founded by experts from Peking University, the company has secured significant venture capital backing from prominent investors like Matrix Partners China and FreeS Fund. Shengyuan Zetong is positioned at the forefront of non-invasive delivery technologies for high-value pharmaceutical products.